Robin Jones to Dacarbazine
This is a "connection" page, showing publications Robin Jones has written about Dacarbazine.
Connection Strength
0.679
-
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Med. 2021 06; 10(11):3565-3574.
Score: 0.189
-
Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. J Clin Oncol. 2017 Oct 20; 35(30):3433-3439.
Score: 0.146
-
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 09; 146(3):531-537.
Score: 0.145
-
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10; 34(8):786-93.
Score: 0.128
-
Pharmacotherapy for liposarcoma: current and emerging synthetic treatments. Future Oncol. 2021 Jul; 17(20):2659-2670.
Score: 0.047
-
Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour. Acta Oncol. 2012 Apr; 51(4):550-4.
Score: 0.024